The article reports on the development of a treatment for hepatitis C virus (HCV) infection by the pharmaceutical firm Abbott that does not contain the ingredient interferon, which can cause adverse side effects. The HCV therapy consists of the antiviral agents protease inhibitor ABT-450, ...
Co-infection with hepatitis B (HBV) and D virus (HDV) is associated with the most severe course of liver disease. Interferon represents the only treatment currently approved. However, knowledge about the impact of interferons on HDV in human hepatocytes
Interferon-free therapy for hep C Dorey, Emma - Chemistry & Industry 被引量: 0发表: 2012年 Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. The aims of this pilot study were to evaluate the safety and efficacy of interferon-alpha 2b for treatment of in ...
(2004). Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology, 39 , 880–890.Gao B, Hong F, Radaeva S. Host factors and failure of interferon-α treatment in hepatitis C virus. Hepatology. 2004; 39 (4):880–890. doi: 10.1002/hep.20139. [ Cross ...
New treatments for chronic hepatitis C:an overview for paediatricians Pegylated interferon(IFN)伪-2a or 2b in combination with ribavirin for children aged 3 years and older is the standard treatment for paediatric chronic hep... D Serranti,G Indolfi,M Resti,... - 《World Journal of Gastroent...
Interferon alfa-n3 was well tolerated and no patient developed neutralizing anti-interferon antibodies during or after the treatment period. Interferon alfa-n3 appears to be effective against hepatitis C virus and deserves further study in larger randomized controlled trials.doi:10.1002/hep.510250232...
For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease inhibitor ABT-450, combined with low-dose ritonavir plus the nonnucleoside NS5B poly...
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C (p1394-1402) However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P = .052). These results suggest that patients...
doi:10.1002/hep.510260330John Wiley & Sons, LtdHepatologyTong MJ, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepa- tology 1997; 26:747-54.Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB,...
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens Background: Treatment of chronic hepatitis C with interferon (IFN)-αand ribavirin has haematotoxic effects. We evaluated the effects of four different IFN... Schmid,M...